Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Poor Timing Takes the Shine Off of CIIG Merger

By Josh Enomoto, InvestorPlace Contributor Dec 18, 2020

Unlike the litany of SPACs flooding the market, CIIC stock offers a truly viable opportunity. But the timing couldn’t be worse.

8 Game-Changing Stocks to Buy for Upside and Innovation

By Josh Enomoto, InvestorPlace Contributor Dec 18, 2020

The markets are a tricky place to navigate in this second wave of the pandemic, so your best hope could be in game-changing stocks.

China’s Consumer Data Is Signaling a Sell for Nio Stock

By Josh Enomoto, InvestorPlace Contributor Dec 18, 2020

Nio stock is easily one of the hottest names of the year, but worrying economic data suggests taking in some of those profits.

9 Stocks to Buy With $5,000 in Starter Money

By Josh Enomoto, InvestorPlace Contributor Dec 17, 2020

If you have a stack of Benjamins lying around and collecting dust, put them to good use with these stocks to buy with $5,000.

9 Stocks for Retirement That Benefit From Shifting Tides

By Josh Enomoto, InvestorPlace Contributor Dec 17, 2020

Stocks for retirement tend to fall under the usual list of suspects. Here are some names to consider that are outside the box.

Novavax Can Still Make Coronavirus Vaccines Great Again

By Josh Enomoto, InvestorPlace Contributor Dec 17, 2020

While Pfizer and Moderna enjoy first-to-market advantage, the reality is that being first in a vaccine race isn’t always the best. Plus, Novavax’s distinct approach could make NVAX stock a strong dark horse.

Can the Gig Economy Continue to Support Adobe Stock?

By Josh Enomoto, InvestorPlace Contributor Dec 17, 2020

Due to the work-from-home pivot, Adobe stock suddenly found itself remarkably relevant, but will 2021 shine brightly as well?

Why It’s Time to Rethink Social Capital Hedosophia Holdings II

By Josh Enomoto, InvestorPlace Contributor Dec 16, 2020

With a housing boom contradicting the implication behind a once-in-a-century pandemic, IPOB stock has been a startling beneficiary. But can the good times go on indefinitely?

The 7 Worst Performing Stocks of 2020

By Josh Enomoto, InvestorPlace Contributor Dec 16, 2020

Perhaps this year like no other has demonstrated the yin-yang effect of the market. While we’ve seen incredible winners, these companies represent the worst performing stocks of 2020.

XpresSpa Bears Might Need Their Own Immunization

By Josh Enomoto, InvestorPlace Contributor Dec 16, 2020

Given the huge technical losses suffered by XSPA stock, it’s no wonder why so many are abandoning ship. However, XpresSpa also remains surprisingly relevant despite the vaccine development.